MANAGEMENT

Kenneth A. Cawkell; BA, LLB -CEO
Ken is a founding principal and CEO of Neurodyn he was involved in the conception and development of the company’s business plan and has been intimately involved in all aspects of the company’s development. He is a member of the Alberta and British Columbia Bar Associations and has over 25 years experience during which he has worked with and sits on the board of numerous public and private biotechnology companies. He currently sits on the board of Helix BioPharma Corp. – TSX  / NYSE Amex where he has been a member of both the executive and board committees. He has been involved in all stages of development of biotech companies, ranging from initial research and development projects through to the development, commercialization and sale of pharmaceutical products.

D.G. Kay Ph.D.  - CSO
Denis is a graduate of Dalhousie (B.Sc. and M.Sc.) and McGill (Ph.D.) Universities.  He is Chief Scientific Officer of Neurodyn Inc. and holds an adjunct professorship in the Department of Pathology and Microbiology at the Atlantic Veterinary College at the University of Prince Edward Island.   He has more than 20 years experience in the development and characterization of small animal models of human diseases ranging from, models of the neurodegenerative diseases ALS and the vacuolar myelopathy associated with HIV infection of the CNS, to a patented model of AIDS (co-inventor).  He is also inventor on two families of Patents pending.

Bill Cheliak PhD. VP Corporate Development
Bill has over 20 years of experience in a wide variety of biotechnology fields, including vaccines, human genetics, drug development, manufacturing and extensive interactions with the pharmaceutical industry. Over the past decade, Bill has secured deals with big and small Pharma as well as raising funding for many ventures. He has executed numerous technology access deals and with academic institutions and research hospitals.